Skip to main content

Advertisement

SpringerLink
Log in

Biosimilars for vasculitis: promise requires validation by quality studies

  • Letter to the Editor
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

AAV:

ANCA-associated vasculitis

ANCA:

Anti-neutrophil cytoplasmic antibody

BD:

Behcet’s disease

GPA:

Granulomatosis with polyangiitis

IFX:

Infliximab

PET-CT:

Positron emission tomography computerized tomography

RTX:

Rituximab

TAK:

Takayasu arteritis

References

  1. Mittal S, Naidu G, Jha S et al (2020) Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05261-7

  2. Misra DP, Naidu GSRSNK, Sharma A (2019) Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitis. Indian J Rheumatol 14:218–228. https://doi.org/10.4103/injr.injr_141_19

    Article  Google Scholar 

  3. Misra DP, Agarwal V (2019) Real-world evidence in rheumatic diseases: relevance and lessons learnt. Rheumatol Int 39:403–416. https://doi.org/10.1007/s00296-019-04248-1

    Article  PubMed  Google Scholar 

  4. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O (2017) Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator. Eur J Rheumatol 4:288–290. https://doi.org/10.5152/eurjrheum.2017.16112

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dincses E, Esatoglu SN, Ozguler Y et al (2019) Biosimilar infliximab for Behçet’s syndrome: a case series. Clin Exp Rheumatol 37(Suppl 121):111–115

    PubMed  Google Scholar 

  6. Lopalco G, Venerito V, Cantarini L, Emmi G, Prisco D, Iannone F (2019) Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet’s disease. Intern Emerg Med 14:719–722. https://doi.org/10.1007/s11739-018-1970-3

    Article  PubMed  Google Scholar 

  7. Park EH, Lee EY, Lee YJ, Ha YJ, Yoo WH, Choi BY, Paeng JC, Suh HY, Song YW (2018) Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int 38:2233–2242. https://doi.org/10.1007/s00296-018-4159-1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Vacchi C, Visentini M, Gragnani L, Fraticelli P, Tavoni A, Filippini D, Saccardo F, Lauletta G, Colantuono S, Atzeni F, Pioltelli P, Manfredi A, Casato M, Zignego AL, Monti G, Pietrogrande M, Galli M, Sebastiani M (2020) Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). Intern Emerg Med. https://doi.org/10.1007/s11739-020-02386-0

  9. Newcastle-Ottawa scale. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed on 14 July 2020

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, 226014, India

    Durga Prasanna Misra & Vikas Agarwal

  2. School of Telemedicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, 226014, India

    Pallavi Patro

Authors
  1. Durga Prasanna Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pallavi Patro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vikas Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The conception and design of the study, acquisition of data, analysis and interpretation of data—DPM, PP and VA. Drafting the article—DPM and PP. Revising it critically for important intellectual content—VA. Final approval of the version to be submitted—DPM, PP and VA. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved—DPM, PP and VA.

Corresponding author

Correspondence to Durga Prasanna Misra.

Ethics declarations

Disclosures

None.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Misra, D.P., Patro, P. & Agarwal, V. Biosimilars for vasculitis: promise requires validation by quality studies. Clin Rheumatol 39, 3149–3151 (2020). https://doi.org/10.1007/s10067-020-05309-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05309-8

Search

Navigation